SGLT2 inhibitors: Sodium-glucose co-transporter 2 (SGLT2) inhibitors were initially developed to treat type 2 diabetes by promoting glucose excretion in the urine [28]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.